118 related articles for article (PubMed ID: 3875634)
1. Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes.
Vlock DR; Kirkwood JM
J Clin Invest; 1985 Aug; 76(2):849-54. PubMed ID: 3875634
[TBL] [Abstract][Full Text] [Related]
2. Incidence of serum antibody reactivity to autologous head and neck cancer cell lines and augmentation of antibody reactivity following acid dissociation and ultrafiltration.
Vlock DR; Scalise D; Schwartz DR; Richter DE; Krause CJ; Baker SR; Carey TE
Cancer Res; 1989 Mar; 49(6):1361-5. PubMed ID: 2924293
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of autologous antibody to human melanoma following acid dissociation and ultrafiltration of serum.
Kirkwood JM; Vlock DR
Cancer Res; 1984 Sep; 44(9):4177-82. PubMed ID: 6744327
[TBL] [Abstract][Full Text] [Related]
4. Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients.
Rossen RD; Crane MM; Morgan AC; Giannini EH; Giovanella BC; Stehlin JS; Twomey JJ; Hersh EM
Cancer Res; 1983 Jan; 43(1):422-9. PubMed ID: 6600161
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of antibody reactivity to melanoma.
Vlock DR; DerSimonian R; Kirkwood JM
J Clin Invest; 1986 Apr; 77(4):1116-21. PubMed ID: 3958183
[TBL] [Abstract][Full Text] [Related]
6. Serial studies of autologous antibody reactivity to squamous cell carcinoma of the head and neck.
Vlock DR; Arnold B; Humpierres J; Schwartz DR; Baker SR; Krause CJ; Swanson N; Carey TE
Cancer Immunol Immunother; 1992; 34(5):329-36. PubMed ID: 1540979
[TBL] [Abstract][Full Text] [Related]
7. [Correlations between complement degradation products and circulating immune complexes in human glomerulonephritis].
Coppo R; De Marchi M; Alloatti S; Segoloni G; Giacchino F; Quarello F; Roccatello D; Bulzomi MR; Piccoli G
Minerva Nefrol; 1979; 26(3):243-50. PubMed ID: 318057
[No Abstract] [Full Text] [Related]
8. [Demonstration of circulating immune complexes using a C1q-solid phase enzyme immunoassay].
Schössler W; Hiepe F; Courault K; Porstmann B; Apostoloff E
Biomed Biochim Acta; 1983; 42(7-8):1027-35. PubMed ID: 6360166
[TBL] [Abstract][Full Text] [Related]
9. Circulating immune complexes in patients with melanoma.
Sztaba-Kania M; Jassem J; Piskorzyńska M; Kondrat W
Neoplasma; 1981; 28(4):491-6. PubMed ID: 7027060
[TBL] [Abstract][Full Text] [Related]
10. Association between circulating immune complexes and renal disease in New Zealand mice.
Nakai Y; Yoshida H; Maruyama N; Shirai T; Hamashima Y
Clin Exp Immunol; 1981 Feb; 43(2):240-5. PubMed ID: 6974065
[TBL] [Abstract][Full Text] [Related]
11. [Circulating immune complexes in the serum of tumor patients].
Alvarez R; García Gómez A; Subiza JL; Domínguez J; Bootello A; Coll J
Rev Esp Oncol; 1982; 29(4):727-34. PubMed ID: 6927370
[TBL] [Abstract][Full Text] [Related]
12. Sequential determination of circulating immune complexes during progressive and regressive phases of mouse mastocytoma.
Bertschmann M; Späth PJ; Nydegger UE; Lüscher EF
J Clin Lab Immunol; 1984 Nov; 15(3):149-54. PubMed ID: 6442352
[TBL] [Abstract][Full Text] [Related]
13. Influence of immune-complex size and antigen-antibody ratio on immune complex detection with monoclonal rheumatoid factor and C1q.
Vanham G; Bloemmen FJ; Ceuppens JL; Stevens EA
J Clin Lab Immunol; 1984 Oct; 15(2):63-8. PubMed ID: 6335179
[TBL] [Abstract][Full Text] [Related]
14. Immune complexes in systemic sclerosis; detection by C1q binding, K-cell inhibition and Raji cell radioimmunoassays.
Hughes P; Cunningham J; Day M; Fitzgerald JC; French MA; Wright JK; Rowell NR
J Clin Lab Immunol; 1983 Mar; 10(3):133-8. PubMed ID: 6601718
[TBL] [Abstract][Full Text] [Related]
15. Circulating immune complex levels in patients with gestational trophoblastic neoplasia.
Rayner AA; Berkowitz R; Steele G; Schur PH; Rodrick ML; Goldstein DP; Harte PJ; Wilson RE; Zamcheck N; Munroe AE
J Natl Cancer Inst; 1982 Jul; 69(1):23-6. PubMed ID: 6285061
[TBL] [Abstract][Full Text] [Related]
16. Critical aspects of the 125I-C1q binding assay for detecting immune complexes in tumor patients.
Krieger G; Bause I; Kneba M; Kehl A; Nagel GA
J Clin Lab Immunol; 1984 Jun; 14(2):87-92. PubMed ID: 6611419
[TBL] [Abstract][Full Text] [Related]
17. Circulating immune complexes in breast cancer patients.
Croce MV; Pasqualini RS; Segal-Eiras A
Medicina (B Aires); 1987; 47(4):371-6. PubMed ID: 3502571
[No Abstract] [Full Text] [Related]
18. Serological evaluation of melanoma patients in a phase I/II trial of vaccinia melanoma oncolysate (VMO) immunotherapy.
Wallack MK; Bash JA; McNally KR; Leftheriotis E
Cancer Detect Prev Suppl; 1987; 1():351-9. PubMed ID: 3155379
[TBL] [Abstract][Full Text] [Related]
19. Chronic liver disease: the detection and characterization of circulating immune complexes.
Brown SE; Steward MW; Viola L; Howard CR; Murray-Lyon IM
Immunology; 1983 Aug; 49(4):673-83. PubMed ID: 6307866
[TBL] [Abstract][Full Text] [Related]
20. Binding characteristics of three complement dependent assays for the detection of immune complexes in human serum.
Krieger G; Kneba M; Bolz I; Volling P; Wessels J; Nagel GA
J Clin Lab Immunol; 1985 Nov; 18(3):129-34. PubMed ID: 3878887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
